More biosimilars mean more access. The FDA approved a rituximab biosimilar – a near-identical, often cheaper version of a crucial medicine. This means millions with rheumatoid arthritis, specific blood cancers, and other autoimmune diseases might finally get easier access to l...
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. MarketThe U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar, developed by Dr. Reddy's Laboratories and to be commercialized by Fresenius Kabi. This approval provides an additional www.fresenius.com